Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 711 participants.
Also called NCT02863419
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 711 participants
- Sponsor
- Registry
-
NCT02863419 -
2015-005210-30
-
- Main results
- Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial
- Other papers using this trial's data
- Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A post hoc subgroup analysis of the PIONEER 1, 3, 4 and 8 trials
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Croatia, Czechia, Germany, Hungary, Japan, Latvia, Poland, Puerto Rico, Slovakia, South Africa, Ukraine, United Arab Emirates
- Registry status
- Completed
Technical summary
Registry record NCT02863419. Randomized; double masking; primary purpose treatment. Start 2016-08-10 (actual); primary completion 2017-08-19 (actual). Results posted on 2019-11-07.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus
- Acronym
- PIONEER 4
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- semaglutide
- Intervention (Drug)
- liraglutide
- Intervention (Drug)
- placebo
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct02863419- Content hash
733cbbbfdf1c7bb60f45c5c244ecffb785dc143b2afadec4b4a579d99e13e186